Modality.AI's multimodal platform produces objective speech measures by analyzing what patients say, and how they say it, without a clinician present and without any special devices. This approach allows for data collection not only at the clinic but also in the convenience of patients' homes, using their own devices. Earlier this year, Verge announced a partnership with Emerald Innovations to incorporate Emerald’s wireless digital biosensors in study participants’ homes to continuously measure key neurological functions affected by ALS.
Key takeaways:
- Verge Genomics is incorporating Modality.AI's automated system to assess speech and language patterns in its Phase 1b proof-of-concept study of its lead drug candidate, VRG50635, a potential treatment for amyotrophic lateral sclerosis (ALS).
- Modality.AI's system allows for objective data collection on changes in speech, which is a common issue for ALS patients, and can provide insights into disease progression.
- The system can analyze patient speech without a clinician present and without any special devices, allowing for data collection at the patient's home using their own devices.
- Verge Genomics had previously announced a partnership with Emerald Innovations to incorporate wireless digital biosensors in study participants' homes to continuously measure key neurological functions affected by ALS.